TechConnect recently spoke with Dan Storey, CEO of DiazaMED. Technologies developed at DiazaMED utilize a non-therapeutic catalysis (Metal Organic Framework) that are integrated onto the surface of implanted medical devices or built into the material using biodegradable linkers. These materials mitigate biofouling processes directly at the blood or tissue-contacting interface of the medical device by working in synergy with biochemical processes.
“We are very pleased that our technology is in the process of being licensed to a major medical device manufacturer,” said Storey. “Diazamed was founded in early 2010 based on work developed in Dr. Melissa Reynolds biomaterials research laboratory at Colorado State University. TechConnect was a great venue for our technology and to present this cutting-edge technologies to a wide audience.”
DiazaMED has developed advanced materials and technologies to create biocompatible surfaces that prevent biofouling and facilitate healthy incorporation into the body. Biofouling on medical implants continues to lead to device failure and complication in patients. Preventing these complications and failures is highly desirable.
DiazaMED’s technology utilizes natural agents that are integrated onto the surface of permanently implanted medical devices or built into the material using biodegradable linkers for short-term applications. These materials mitigate detrimental biofouling processes directly at the tissue contacting interface of the medical device. DiazaMED’s technology acts as a catalyst to produce localized nitric oxide. After a short time period the body’s cells coat the device and naturally continue producing nitric oxide preventing biofouling for an extended period of time.
These platform materials and coatings for medical devices have several advantageous features, including:
• Controllable short- and long-term durations
• Prevention of platelet activation and reductions in surface thrombosis
• Reduction in rates of infection and inflammation
• Improvements in natural wound healing processes
• Synthetic surfaces are safe and non-cytotoxic as measured by ISO 10993 standards
• Materials can be integrated into current device manufacturing processes such as extrusion, dip coating, and spray coating
• Materials are suitable for handling and storage in routine clinical applications
DiazaMED is now planning a fundraising round to expand their technologies. Plans are to raise money to create their own products, obtain FDA approval and after a limited market release, sell the approved product to a major medical device company, thus reducing the approval risk.
To learn more please visit: www.diazamed.com.